Mark Lies

The comprehensive characterization of multispecific antibodies is essential to the development of safe and efficacious cancer treatments.

The application of various new methods and instruments for the analysis of multispecifics is discussed as a means of highlighting their ability to facilitate the development of these important new modalities.

This article focuses on ways to accelerate glycan screening data analysis, while keeping high reproducibility.A major focus of the pharmaceutical industry is the production and development of biologics-therapeutics produced via biological means-to provide novel treatments for diseases with unmet clinical needs. A large percentage of biologics under development are proteins, such as monoclonal antibodies (mAbs), fusion proteins, antibody–drug conjugates (ADCs), and enzymes. The structures of these protein drugs are made more complex by post‑translational modifications (PTMs).